PDE

(redirected from Phosphodiesterases)
Also found in: Dictionary, Medical, Encyclopedia.
AcronymDefinition
PDEPennsylvania Department of Education
PDEPartial Differential Equation
PDEPhosphodiesterases
PDEPlug-In Development Environment
PDEPulse Detonation Engine
PDEParamount Digital Entertainment
PDEPlataforma en Defensa de l'Ebre (Catalan: Platform for the Defence of the River Ebre)
PDEPersonal Digital Entertainment
PDEPrescription Drug Event
PDEProduct Data Exchange
PDEPresent-Day English
PDEPosition Determining Entity
PDEPhoton Detection Efficiency
PDEPlataforma en Defensa del Ebro (Spanish: Platform for the Defence of the River Ebre)
PDEProject Development Engineer
PDEPortable Electronic Device
PDEProduct Design Engineer
PDEPyridoxine-Dependent Epilepsy
PDEPrimary Designated Engineer
PDEProcess Development Engineer
PDEPrimark Decision Economics
PDEProduction Estimate
PDEPotential Daily Exposure
PDEPhiladelphia Drug Exchange
PDEProjected Operational Environment
PDEPropagation Delay Estimation
PDEPre-Emphasis/De-Emphasis
PDEPreliminary Determination of Epicenter(s) (USGS)
PDEPaddle Drive Electronics
PDEProject/Program Director, Electronics
PDEPreliminary Data Element
PDEPermission Display Engine
PDEPredictive Density Estimation
PDEProcessing Development Environment (software)
PDEPersonal Development Education
PDEProfessional Development Event
PDEPurely Domestic Enterprise (finance)
PDEPrimary Developmental Education (US Air Force)
PDEPlanning, Decision, and Execution
References in periodicals archive ?
The IC50 values for inhibition of urease, phosphodiesterase and protein glycation were calculated using EZ-fit Enzyme Kinetics Program (Parella Scientific, Amherst, USA).
2008, wherein the introduction of fluoro groups enhanced inhibitory potential of phenyl alkyl ketones against phosphodiesterase 4 (PDE4) [81].
Shortly, the phosphodiesterase I (NPPI) inhibition may be modulated by complexation with Pd(II), position of substituents, steric hindrance, hydrogen bonding and electronic effects.
Top 10 Countries for Phosphodiesterases Research (Ranked by Number of Senior Researchers):
Leading Organisations in Phosphodiesterases Research Include:
The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Phosphodiesterases research field.
It achieves this selective activity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
In addition to NRs and GPCRs, additional modules of the DrugTarget Database include ion channels, protein kinases, protein phosphatases, phosphodiesterases, transporters, and proteases.
SAANDs selectively trigger apoptosis in cancerous and precancerous cells by inhibiting certain cyclic GMP phosphodiesterases that company scientists and collaborators have shown to be over-expressed in a variety of tumor types.
Background: Phosphodiesterase 4 (PDE4) inhibitors negatively modulate many inflammatory responses, and some of these pharmacological effects are mediated by inhibition of PDE4B in inflammatory cells.
sup][5] By increasing intracellular cAMP level, phosphodiesterase 4 (PDE4) inhibitors are being developed as anti-inflammatory agents for the treatment of chronic inflammatory disorders such as asthma, chronic obstructive pulmonary disease, and psoriasis.
The results of this study continue to support clinical proof-of-principle for exisulind, a cyclic GMP phosphodiesterase inhibitor, in the prevention of growth of precancerous adenomatous polyps of the colon," said Rifat Pamukcu, MD, chief scientific officer of Cell Pathways, Inc.
Full browser ?